Litigation expenses and recall costs related to Johnson & Johnson’s recall of the DePuy ASR hip implant cost the health care conglomerate $271 million in profits during the 1st quarter.
Shares of Johnson & Johnson (NYSE:JNJ) closed up a hair yesterday after the company said it added 12.5% to its bottom line, ending the day at $64.22 per share after the J&J raised its earnings guidance for the year by a pair of pennies.
